CPC C07K 16/30 (2013.01) [A61K 35/17 (2013.01); C07K 14/4747 (2013.01); C07K 14/54 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); A61K 2039/505 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/70 (2013.01); C07K 2319/74 (2013.01)] | 11 Claims |
1. An isolated induced pluripotent stem cell comprising a polynucleotide encoding a chimeric antigen receptor molecule comprising, in an N-terminus to C-terminus orientation: an ectodomain comprising an antigen recognition region; a hinge; a transmembrane domain comprising a transmembrane region of NKG2D (cluster of differentiation 314 or CD314) in reverse orientation as compared to native NKG2D that natively has an extracellular C-terminus; and an endodomain comprising a functional signaling domain that activates a Natural Killer (NK) cell differentiated from the induced pluripotent stem cell wherein the functional signaling domain comprises an intracellular domain (ICD) from:
(a) 2B4 (cluster of differentiation 244 or CD244);
(b) 41BB (cluster of differentiation 137 or CD137);
(c) DAP12 (DNAX activation protein of 12 kDa) or DAP10;
(d) 2B4 and 41BB; or
(e) IL21R;
and further wherein the functional signaling domain comprises a signaling domain from CD3 zeta (CD3ζ).
|